ArticleClinical pharmacology and therapeutics2021
Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants.
Open access · hybridAbstract read
In one paragraph
Article in Clinical pharmacology and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Emerging Treatments in Neonatal Fungal Infections: Progress and Prospects.Paediatric drugs · 2025Review
- Physiologically Based Pharmacokinetic Modeling of Tofacitinib: Predicting Drug Exposure and Optimizing Dosage in Special Populations and Drug-Drug Interaction Scenarios.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Coupling Pre- and Postnatal Infant Exposures with Physiologically Based Pharmacokinetic Modeling to Predict Cumulative Maternal Levetiracetam Exposure During Breastfeeding.Clinical pharmacokinetics · 2024Article
- Triazole antifungal drug interactions-practical considerations for excellent prescribing.The Journal of antimicrobial chemotherapy · 2024Review
- Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach.Cancer chemotherapy and pharmacology · 2024Article
- Prediction of drug-drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach.BMC pharmacology & toxicology · 2024Article
- The Complexity of Bariatric Patient's Pharmacotherapy: Sildenafil Biopharmaceutics and Pharmacokinetics before vs. after Gastric Sleeve/Bypass.Pharmaceutics · 2023Article
- Physiologically Based Pharmacokinetics Modeling in the Neonatal Population-Current Advances, Challenges, and Opportunities.Pharmaceutics · 2023Review
- Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment.Scientific reports · 2023Article
- Novel Method for Early Prediction of Clinically Significant Drug-Drug Interactions with a Machine Learning Algorithm Based on Risk Matrix Analysis in the NICU.Journal of clinical medicine · 2022Article
- Physiologically based pharmacokinetic modeling of tadalafil to inform pediatric dose selection in children with pulmonary arterial hypertension.CPT: pharmacometrics & systems pharmacology · 2022Article
- Changes in CYP3A4 Enzyme Expression and Biochemical Markers Under Acute Hypoxia Affect the Pharmacokinetics of Sildenafil.Frontiers in physiology · 2022Article
- Ontogeny of Scaling Factors for Pediatric Physiology-Based Pharmacokinetic Modeling and Simulation: Microsomal Protein Per Gram of Liver.Drug metabolism and disposition: the biological fate of chemicals · 2022Article
- Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy.Clinical pharmacology and therapeutics · 2021Article
- Characterization of fluorescent probe substrates to develop an efficient high-throughput assay for neonatal hepatic CYP3A7 inhibition screening.Scientific reports · 2021Article
- Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.Drug metabolism and disposition: the biological fate of chemicals · 2021Article
- Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development.AAPS PharmSciTech · 2021Review
- Pediatric Drug-Drug Interaction Evaluation: Drug, Patient Population, and Methodological Considerations.Journal of clinical pharmacology · 2021Review
- Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: Implication of herb-drug interactions in COVID-19 pharmacotherapy.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 2 countries.
Sara N SalernoDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Andrea EdgintonSchool of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada.
Jacqueline G GerhartDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Matthew M LaughonDepartment of Pediatrics, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Namasivayam AmbalavananDivision of Neonatology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Gregory M SokolDivision of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Chi D HornikDepartment of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.
Dan StewartUniversity of Louisville Norton Children's Hospital, Louisville, Kentucky, USA.
Mary MillsDuke Clinical Research Institute, Durham, North Carolina, USA.
Karen MartzThe Emmes Company, LLC, Rockville, Maryland, USA.
Daniel GonzalezDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee
University of North Carolina at Chapel Hill · USClinical Research Institute · USDuke Medical Center · USEmmes (United States) · USIndiana University – Purdue University Indianapolis · USKosair Children's Hospital · USUniversity of Alabama at Birmingham · USUniversity of Waterloo · CA
Funding
UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program-Evaluation SupplementT32GM086330 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER, Daniel Gonzalez · 2011 to 2026
$8.5MPhysiologically-Based Pharmacokinetic Modeling to Guide Drug Dosing in Children with ObesityR01HD096435 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUMOND, JULIE BRUMER · 2018 to 2022
$2.0MSafety of Sildenafil in Premature Infants at Risk of Bronchopulmonary DysplasiaR01FD006099 · FDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LAUGHON, MATTHEW · 2018 to 2022
$2.0MEnhancement Training for the Next Generation of Translational Ph.D. ScientistsT32GM122741 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOLBERG, ALISA S., YEH, JEN JEN · 2018 to 2022
$898kUse of Physiologically-Based PK/PD Models to Streamline Drug ApprovalsK23HD083465 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GONZALEZ, DANIEL · 2015 to 2019
$727kMentorship of Early-Career Clinicians in Bronchopulmonary Dysplasia Drug TherapiesK24HL143283 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LAUGHON, MATTHEW · 2019 to 2023
$613kFDA HHS R01 FD006099NHLBI NIH HHS K24 HL143283NICHD NIH HHS HHSN275201000003CNICHD NIH HHS HHSN275201000003INICHD NIH HHS HHSN275201700002CNICHD NIH HHS K23 HD083465NICHD NIH HHS R01 HD096435NIGMS NIH HHS T32 GM086330NIGMS NIH HHS T32 GM122741
Abstract
Physiologically-based pharmacokinetic (PBPK) modeling can potentially predict pediatric drug-drug interactions (DDIs) when clinical DDI data are limited. In infants for whom treatment of pulmonary hypertension and prevention or treatment of invasive candidiasis are indicated, sildenafil with fluconazole may be given concurrently. To account for developmental changes in cytochrome P450 (CYP) 3A, we determined and incorporated fluconazole inhibition constants (K
Indexed as
AdolescentAdultAgedArea Under CurveCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsDrug InteractionsFemaleFluconazoleHumansInfant, PrematureMaleMiddle AgedModels, BiologicalSildenafil CitrateYoung AdultCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsFluconazoleSildenafil Citrate
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.